Cover Image
市場調查報告書

非何杰金氏淋巴瘤 (NHL) - 瀰漫性大細胞型B細胞淋巴瘤:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

NHL: Diffuse large Bcell lymphoma: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365184
出版日期 內容資訊 英文 219 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
非何杰金氏淋巴瘤 (NHL) - 瀰漫性大細胞型B細胞淋巴瘤:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 NHL: Diffuse large Bcell lymphoma: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年05月01日 內容資訊: 英文 219 Pages
簡介

本報告提供瀰漫性大細胞型B細胞淋巴瘤 (DLBCL)的已上市及臨床實驗中 (開發平台上)的治療藥相關分析,整體市場及各產品的收益額的估計值 (今後10年份),市場規模最大的/成長率最高的有潛力市場,目前主力品牌藥,目前可解除未滿足需求的治療藥,學名藥和生技仿製藥的上市對市場產生的影響等相關調查。

市場預測:瀰漫性大細胞型B細胞淋巴瘤

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Afinitor (Everolimus)
  • Rituximab的生技仿製藥
  • Gazyva (obinutuzumab)
  • Imbruvica (ibrutinib)
  • Revlimid (lenalidomide)
  • Rituxan (rituximab)
  • Velcade (bortezomib)
  • 一次調查技術

治療方法:瀰漫性大細胞型B細胞淋巴瘤

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢

流行病學:瀰漫性大細胞型B細胞淋巴瘤

  • 摘要整理
  • 疾病的背景情況
  • 資訊來源、分析方法
  • 市場預測:非何杰金氏淋巴瘤 (NHL) 全體
  • 市場預測:各類型 (含瀰漫性大細胞型B細胞性、濾胞性、套細胞淋巴瘤)
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:瀰漫性大細胞型B細胞淋巴瘤

  • 摘要整理
  • 產品概要
  • 產品簡介:Rituxan

開發中產品:瀰漫性大細胞型B細胞淋巴瘤

  • 摘要整理
  • 臨床實驗開發平台概要
  • 目標產品簡介
  • 最近,臨床實驗中止的藥物
  • 產品簡介 (最後階段):Afinitor
  • 產品簡介 (最後階段):Gazyva
  • 產品簡介 (最後階段):Imbruvica
  • 產品簡介 (最後階段):Keytruda
  • 產品簡介 (最後階段):Revlimid
  • 產品簡介 (最後階段):Velcade

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5900

An increase in disease prevalence and the launch of new targeted therapies across a range of treatment settings will drive the growth of the diffuse large B-cell lymphoma (DLBCL) market during 2016-25 despite Rituxan's patent expiry.

This report addresses the following questions:

  • What will drive the growth of the DLBCL market during 2016-25?
  • Which geographical market will be the most lucrative and which will experience the fastest growth?
  • Which branded therapies will have the largest impact on the DLBCL market?
  • Which therapies will target patient populations that represent unmet needs in DLBCL?
  • When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

TABLE OF CONTENTS

FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Afinitor (everolimus)
  • 5. Biosimilar rituximab
  • 6. Gazyva (obinutuzumab)
  • 7. Imbruvica (ibrutinib)
  • 8. Revlimid (lenalidomide)
  • 9. Rituxan (rituximab)
  • 10. Velcade (bortezomib)
  • 11. Primary Research Methodology

TREATMENT: DIFFUSE LARGE B-CELL LYMPHOMA

  • 12. Executive Summary
  • 13. Primary Research Methodology
  • 14. Disease Definition and Diagnosis
  • 15. Patient Segmentation
  • 16. Country Treatment Trees
  • 17. Current Treatment Options
  • 18. Prescribing Trends

EPIDEMIOLOGY: DIFFUSE LARGE B-CELL LYMPHOMA

  • 19. Executive Summary
  • 20. Disease Background
  • 21. Sources and Methodology
  • 22. Forecast: NHL Overall
  • 23. Forecast: NHL Subtypes (incl. DLBCL, FL, and MCL)
  • 24. Epidemiologist Insight
  • 25. Strengths and Limitations

MARKETED DRUGS: DIFFUSE LARGE B-CELL LYMPHOMA

  • 26. Executive Summary
  • 27. Product Overview
  • 28. Product profile: Rituxan

PIPELINE: DIFFUSE LARGE B-CELL LYMPHOMA

  • 29. Executive Summary
  • 30. Clinical Pipeline Overview
  • 31. Target Product Profile
  • 32. Recently Discontinued Drugs
  • 33. Product profile (late stage): Afinitor
  • 34. Product profile (late stage): Gazyva
  • 35. Product profile (late stage): Imbruvica
  • 36. Product profile (late stage): Keytruda
  • 37. Product profile (late stage): Revlimid
  • 38. Product profile (late stage): Velcade
Back to Top